The Vertical Automated Profile
More Comprehensive Test
The VAP Test uses an advanced technology that provides a more accurate, individualized picture of your heart disease and diabetes risk so you and your doctor can take steps to prevent a future heart attack. For example, the VAP Expanded Lipid Profile measures not only the basic information provided by the routine cholesterol test, but also identifies hidden cholesterol problems that can increase your risk of developing heart disease or diabetes—even if your routine cholesterol test results are "normal." As a result, the VAP Test was named one of "Ten Ways to Live Longer" by Forbes.com and was selected as one of "Five Tests Worth Paying For" by The Wall Street Journal.
Why the Need for a VAP Test
Heart disease is the leading killer of both men and women in the United States—causing the deaths of more than 500,000 people each year. Unfortunately, getting "normal" results back from a routine cholesterol test doesn't mean one is safe from heart disease. That's because routine cholesterol tests fail to identify half of those at risk—robbing many people of the opportunity to take preventive steps that might save their lives.
The VAP Test provides valuable information that can identify hidden heart disease risks. It breaks down cholesterol beyond HDL (high-density lipoprotein, the "good" cholesterol), LDL (low-density lipoprotein, the "bad" cholesterol), and triglycerides—providing new information that can help your doctor better assess and manage your heart disease risk. VAP Tests also help identify the metabolic syndrome-which leads to diabetes and heart disease, and affects a staggering 55 million Americans.
The role of cholesterol testing in clinical practice is to stratify a patient's risk for cardiovascular disease and to direct therapy to reduce that risk. Accuracy and comprehensiveness in cholesterol testing are critical, especially in light of lower LDL goals, as well as the need to measure and treat a variety of cholesterol subclasses and components. As a result, the heart disease and diabetes risk factors reported by the the VAP Test technology are the best choice for patients at risk for cardiometabolic disorders.
Apolipoprotein B100 (apoB100)
Several studies have shown that apolipoprotein B (apoB) is a better risk predictor for coronary heart disease (CHD) than several other risk factors, including LDL cholesterol., Since each atherogenic lipoprotein (Lp(a), LDL, IDL, and VLDL) contains one molecule of apoB, apoB concentration therefore represents the total number of atherogenic particles. Atherotech has developed a novel procedure to report apoB utilizing non-HDL-cholesterol along with lipoprotein density distribution using the patented VAP ultracentrifugation method. Atherotech has thoroughly validated this new procedure by comparing the VAP apoB with measured apoB using serum from 1,797 patients. This comparison has yielded an excellent correlation coefficient (r = 0.97) with bias of only 0.8%.
1. AMORIS Study, Lancet, 2001; 358: 2026-33.
2. Health Professionals Follow-Up Study, Circulation, 2005; 112: 3375-83.
One of the key benefits of the VAP technology is a direct-measured LDL. The routine cholesterol panel, which estimates LDL using the Friedewald formula, provides only a 40% predictive value for coronary heart disease. In contrast, the VAP Test, which directly measures LDL, identifies a far greater number of patients at risk for heart disease.
Because of the concerns concerns regarding the reliability of estimated LDL, the NCEP ATP III guidelines recommend that direct LDL measurement methods be used as they are unaffected by triglycerides and patient fasting. In fact, estimated LDL cholesterol levels become significantly inaccurate in patients with heart disease or the equivalent (LDL goal <70-100 mg/dL). Estimated LDL cholesterol levels often fail to accurately classify risk for those patients with triglycerides >200 mg/dL.